Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › eribulin

eribulin

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of eribulin

49 trials tracked of eribulin: 7 in phase 3 or 4 and 5 with published results. The most-cited published study has 494 citations.

49Trials tracked
7Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 37 Phase 1 4 Other / NA 1
  1. Phase 3 Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Completed · 494 cited
  2. Phase 3 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer Completed · 424 cited
  3. Phase 3 Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) Completed · 153 cited
  4. Phase 3 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine Completed · 24 cited
  5. Phase 3 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer Completed · 18 cited
  6. Phase 4 Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer Completed
Show 43 more trials
  1. Phase 3 E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Completed
  2. Phase 2 Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer Completed
  3. Phase 2 Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed
  4. Phase 2 Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer Completed
  5. Phase 2 Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer Completed
  6. Phase 2 S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed
  7. Phase 2 A Confirmation Study of Eribulin in Combination With Capecitabine Completed
  8. Phase 2 E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed
  9. Phase 2 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Completed
  10. Phase 2 A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer Completed
  11. Phase 2 Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer Completed
  12. Phase 2 Study of E7389 for Advanced or Metastatic Breast Cancer Completed
  13. Phase 2 Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer Completed
  14. Phase 2 Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients Completed
  15. Phase 2 Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate Completed
  16. Phase 2 Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer Completed
  17. Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) Completed
  18. Phase 2 Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Completed
  19. Phase 2 Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) Completed
  20. Phase 2 Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Completed
  21. Phase 2 A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer Completed
  22. Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer Completed
  23. Phase 2 Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Completed
  24. Phase 2 Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer Completed
  25. Phase 2 Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer Completed
  26. Phase 2 Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer Completed
  27. Phase 2 Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Completed
  28. Phase 2 Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment Completed
  29. Phase 2 An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) Completed
  30. Phase 2 A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer Completed
  31. Phase 2 Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer Completed
  32. Phase 2 Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes Completed
  33. Phase 2 Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Completed
  34. Phase 2 Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 Completed
  35. Phase 2 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Completed
  36. Phase 2 A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer Completed
  37. Phase 2 Eribulin and Lenvatinib in Advanced Solid Tumors Completed
  38. Phase 2 Eribulin in HER2 Negative Metastatic BrCa Completed
  39. Phase 1 Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer Completed
  40. Phase 1 QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors Completed
  41. Phase 1 A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors Completed
  42. Phase 1 This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas Completed
  43. N/A Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies Completed

Showing the 49 most-cited and recently-updated of 49 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
OB/GYN & Women's Health RCT
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer. Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Jun 4, 2026
Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments
Oncology Meta-analysis
Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments Protocol outlines options for second-line soft tissue sarcoma treatments
This is a protocol for a systematic review and network meta-analysis. It will evaluate second-line pharmacological regimens for advanced sof…
A new protocol maps second-line drug choices for advanced soft tissue sarcoma patients previously treated with anthracyclines, noting curren…
medRxiv May 24, 2026